Healthy Returns: New FDA rules affect copycat GLP-1s, and Apple adds health tools to its latest Watch

The FDA's introduction of a 'green list' for compliant GLP-1 raw ingredient suppliers, aimed at enhancing safety by detaining non-listed imports, led to over 2% share declines for major GLP-1 manufacturers Eli Lilly and Novo Nordisk. Analysts interpret this action as insufficient to fully curb competition from quality-controlled compounded drugs, implying continued market presence for these alternatives despite branded product availability. This suggests branded drugmakers will likely need to intensify litigation efforts to protect their market share against compounded versions.

Analysis

The U.S. Food and Drug Administration's new 'green list' for foreign suppliers of GLP-1 ingredients represents a nuanced regulatory development with negative implications for Eli Lilly and Novo Nordisk, as reflected by the immediate 2% decline in their share prices. While the FDA's stated goal is to enhance patient safety by blocking imports from uninspected facilities, the policy effectively legitimizes compounded versions of weight-loss drugs made with ingredients from approved suppliers. Analyst commentary from BMO Capital Markets suggests this action falls short of the full-stop ban manufacturers had hoped for, implying the FDA is comfortable with quality-controlled compounded drugs co-existing with branded treatments like Wegovy and Zepbound, even with supply shortages resolved. This creates a persistent competitive overhang, particularly for Novo Nordisk, which previously cut its Wegovy sales guidance due to compounding competition. Consequently, the primary recourse for Eli Lilly and Novo Nordisk appears to be aggressive litigation against compounding pharmacies and telehealth providers, with a potential lawsuit against Hims & Hers highlighted as a pivotal event to watch.

Key Decisions for Investors

• Investors in Eli Lilly and Novo Nordisk should re-evaluate long-term growth forecasts, as the FDA's new policy formalizes a competitive channel for compounded GLP-1s, potentially creating a persistent headwind for branded drug pricing and market share.
• Monitor legal developments closely, as successful litigation by Novo Nordisk and Eli Lilly against major distributors of compounded drugs, such as a potential lawsuit against Hims & Hers, now represents the most significant near-term catalyst to mitigate this competitive threat.
• Consider the risk that this regulatory framework establishes a new normal where high-quality compounded drugs capture a permanent segment of the market, which could warrant adjusting positions in LLY and NVO if their legal strategies prove ineffective in curbing this competition.